反応式
Cl.[CH3:2][S:3]([C:6]1[CH:11]=[CH:10][C:9]([N:12]2[C:16]3=[N:17][CH:18]=[N:19][C:20]([O:21][CH:22]4[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]4)=[C:15]3[CH:14]=[N:13]2)=[CH:8][CH:7]=1)(=[O:5])=[O:4].CCN(CC)CC.[CH2:35]([C:37]([CH2:39]Br)=[O:38])[CH3:36].C(O)(C(F)(F)F)=O>O1CCOCC1.CC#N.O>[CH3:2][S:3]([C:6]1[CH:11]=[CH:10][C:9]([N:12]2[C:16]3=[N:17][CH:18]=[N:19][C:20]([O:21][CH:22]4[CH2:27][CH2:26][N:25]([CH2:39][C:37](=[O:38])[CH2:35][CH3:36])[CH2:24][CH2:23]4)=[C:15]3[CH:14]=[N:13]2)=[CH:8][CH:7]=1)(=[O:4])=[O:5]参加物
反応物 4
生成物 1
試薬・触媒・溶媒 3
反応条件
- 温度
- 100 °C
実験手順
To a solution of 1-(4-methanesulfonyl-phenyl)-4-(piperidin-4-yloxy)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride (30.0 mg, 0.073 m mmol) and Et3N (35 μL) in dioxane (1.5 mL) was added bromomethyl ethyl ketone (22 μL, 0.219 mmol). The mixture was heated by microwave irradiation at 100° C. for 10 min. The mixture was diluted with CH3CN (3 mL) and purified by reverse-phase HPLC: Phenomenex® Luna C18 column (10μ, 250×21.2 mm), 5% (v/v) CH3CN (containing 1% v/v TFA) in H2O (containing 1% v/v TFA) gradient to 95% H2O, 20 mL/min, λ=214 nm to give Compound A168 (7.8 mg, 0.014 mmol, 19% yield) isolated as a white solid. HPLC/MS: Alltech® Prevail C18 column (5μ, 50×4.6 mm), 5% v/v CH3CN (containing 1% v/v TFA) in H2O (containing 1% v/v TFA) gradient to 99% v/v CH3CN in H2O, 3.5 mL/min, tr=1.69 min, ESI+=444.3 (M+H).
後処理
- custompurified by reverse-phase HPLC
- additionPhenomenex® Luna C18 column (10μ, 250×21.2 mm), 5% (v/v) CH3CN (containing 1% v/v TFA) in H2O (
- additioncontaining 1% v/v TFA) gradient to 95% H2O, 20 mL/min, λ=214 nm
- customto give Compound A168 (7.8 mg, 0.014 mmol, 19% yield)
- customisolated as a white solid
出典と根拠
- ORDレコード
- ord-9959e18e33bf492db1f41ac49a2f637b
- 出典データセット
- uspto-grants-2013_04
- 特許番号
- US08410119B2
関連ノート
読み込み中…